Skip to content
OpenCapital
Get started

Harrow HROW VEVYE — Revenue

Other product segments

Other Products
$7.83M+719%
IHEEZO
$1.85M-64.6%
Other Revenues
$73K—

Similar metrics at other companies

Innoviva, Inc. logo
INVAZEVTERA — Revenue
$438K—
Sarepta Therapeutics, Inc. logo
SRPTElevidys — Revenue
$101.97M-72.8%
Jazz Pharmaceuticals logo
JAZZVyxeos — Revenue from Contract with Customer, Excluding Assessed Tax
$26.6M-9.8%
Jazz Pharmaceuticals logo
JAZZXywav — Revenue from Contract with Customer, Excluding Assessed Tax
$408.2M+18.4%
Allient Inc. logo
ALNTVehicle — Revenue
$24.63M+7.2%
Mobileye Global Inc. logo
MBLYMobileye — Revenue
$549M+28.3%

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.81B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's vevye — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's VEVYE — revenue?
Harrow (HROW) reported VEVYE — revenue of $20.95M in Q1 2026.
How has Harrow's VEVYE — revenue changed year-over-year?
Harrow's VEVYE — revenue decreased by 2.6% year-over-year, from $21.52M to $20.95M.
What is the long-term trend for Harrow's VEVYE — revenue?
Over 2 years (2023 to 2025), Harrow's VEVYE — revenue has grown at a 608.7% compound annual growth rate (CAGR), from $1.77M to $88.69M.
What does VEVYE — revenue mean?
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product or service line after adjusting for taxes collected from customers. It serves as a primary indicator of the product's market adoption, commercial success, and contribution to the company's overall top-line growth. Tracking this figure allows investors to evaluate the scaling trajectory and demand for the specific asset within the company's portfolio.